LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company, announced that management has begun planning for the Company's anticipated attendance at the World Health Expo 2027 in Dubai, United Arab Emirates, as part of its broader strategy to evaluate international healthcare expansion opportunities. The Company believes this event will provide an important opportunity to engage with healthcare leaders, technology innovators, and potential strategic partners from around the world.
Management views the planned participation as a means to support ongoing assessments of international commercialization opportunities for its developing digital healthcare ecosystem, which includes telehealth infrastructure, healthcare coordination technologies, pharmacy integration initiatives, insurance and payment accessibility solutions, and artificial intelligence-driven platforms such as CardioAI, PulmoAI, and NeuroAI. The World Health Expo may also offer opportunities to evaluate potential strategic relationships, licensing opportunities, and regional collaborations while gaining insight into emerging trends in healthcare innovation and precision medicine.
The planned attendance builds upon the Company's recent international engagement initiatives, including attendance at HLTH Europe, and complements its continued expansion throughout Latin America. This includes recently announced strategic initiatives in Venezuela and an ongoing evaluation of expansion opportunities in Colombia. Dr. Kevin Rodan Levy, Chief Executive Officer, stated that the event is expected to provide an outstanding opportunity to engage with global healthcare leaders and explore strategic relationships that may support the development and international expansion of the LataMed AI platform.
Management emphasized that the attendance remains in the planning stage and forms part of a broader evaluation of future international growth opportunities. No assurance can be provided regarding the completion of any strategic relationships, licensing arrangements, or commercial agreements arising from the planned attendance. The Company also announced that its previously announced 5-for-1 forward stock split and mandatory share exchange are expected to become effective on July 15, 2026, subject to customary administrative processing. Shareholders holding shares through brokerage accounts generally are not expected to take action, while those with physical certificates may exchange them through the Company's transfer agent.
LataMed AI Corp. is a development-stage company focused on building telehealth infrastructure, healthcare coordination tools, and AI-enabled solutions for emerging markets. The Company's strategy centers on developing technology platforms to support healthcare access, patient engagement, provider coordination, and data-driven operations, with an initial regional focus on Latin America. For more information, visit https://latamed.ai.
